Nazli Dizman, MD

• Daniel P. Petrylak

Immunotherapy; Medical Oncology; Molecular Targeted Therapy; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Microbiome

• Genomic profiling in renal cell carcinoma.Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nature Reviews. Nephrology 2020, 16: 435-451. PMID: 32561872, DOI: 10.1038/s41581-020-0301-x.
• Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma.Dizman N, Hsu J, Bergerot PG, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK, Pal SK. Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma. Cancer Medicine 2020 PMID: 33135866, DOI: 10.1002/cam4.3569.
• Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis.Dizman N, Lyou Y, Salgia N, Bergerot PG, Hsu J, Enriquez D, Izatt T, Trent JM, Byron S, Pal S. Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. Journal For Immunotherapy Of Cancer 2020, 8 PMID: 32661119, PMCID: PMC7359179, DOI: 10.1136/jitc-2020-000953.
• Immune checkpoint inhibitors and timing of administration.Dizman N, Velazquez AI, Duma N. Immune checkpoint inhibitors and timing of administration. The Lancet. Oncology 2022, 23: e56. PMID: 35114125, DOI: 10.1016/S1470-2045(22)00009-2.
• Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors.Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK, Pal SK. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors. European Urology 2020, 78: 498-502. PMID: 32828600, DOI: 10.1016/j.eururo.2020.07.011.
• Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.Chehrazi-Raffle A, Meza L, Alcantara M, Dizman N, Bergerot P, Salgia N, Hsu J, Ruel N, Salgia S, Malhotra J, Karczewska E, Kortylewski M, Pal S. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. Journal For Immunotherapy Of Cancer 2021, 9 PMID: 33688021, PMCID: PMC7944971, DOI: 10.1136/jitc-2020-002009.
• Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis.Araujo DV, Wells JC, Hansen AR, Dizman N, Pal SK, Beuselinck B, Donskov F, Gan CL, Yan F, Tran B, Kollmannsberger CK, de Velasco G, Yuasa T, Reaume MN, Ernst DS, Powles T, Bjarnason GA, Choueiri TK, Heng DYC, Dudani S. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. Journal Of Geriatric Oncology 2021 PMID: 33674246, DOI: 10.1016/j.jgo.2021.02.022.
• Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.Gan CL, Dudani S, Wells JC, Donskov F, Pal SK, Dizman N, Rathi N, Beuselinck B, Yan F, Lalani AA, Hansen A, Szabados B, de Velasco G, Tran B, Lee JL, Vaishampayan UN, Bjarnason GA, Subasri M, Choueiri TK, Heng DYC. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Medicine 2021, 10: 1212-1221. PMID: 33463028, PMCID: PMC7926018, DOI: 10.1002/cam4.3717.
• Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, Galsky MD, Vaishampayan U, De Giorgi U, Gupta S, Burris HA, Soifer HS, Li G, Wang H, Dambkowski CL, Moran S, Daneshmand S, Rosenberg JE. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer 2020, 126: 2597-2606. PMID: 32208524, PMCID: PMC7515773, DOI: 10.1002/cncr.32806.
• Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients.Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N. Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. Journal Of Geriatric Oncology 2020, 11: 724-726. PMID: 31402176, DOI: 10.1016/j.jgo.2019.07.002.
• Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling.Dizman N, Salgia M, Ali SM, Wu H, Arvanitis L, Chung JH, Pal SK. Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling. Clinical Genitourinary Cancer 2020, 18: e289-e292. PMID: 31882336, DOI: 10.1016/j.clgc.2019.11.020.
• Sequencing Therapies for Metastatic Renal Cell Carcinoma.Dizman N, Arslan ZE, Feng M, Pal SK. Sequencing Therapies for Metastatic Renal Cell Carcinoma. The Urologic Clinics Of North America 2020, 47: 305-318. PMID: 32600533, DOI: 10.1016/j.ucl.2020.04.008.
• Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.Dizman N, Bergerot P, Bergerot C, Lanman RB, Raymond VM, Banks KC, Jones J, Pal SK. Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile. European Urology 2018, 73: 308-310. PMID: 28844598, DOI: 10.1016/j.eururo.2017.08.006.
• Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status.Bergerot CD, Philip EJ, Bergerot PG, Hsu J, Dizman N, Salgia M, Salgia N, Vaishampayan U, Battle D, Loscalzo M, Dale W, Pal SK. Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status. Cancer 2020 PMID: 33007114, DOI: 10.1002/cncr.33238.
• First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan UN, Wood LA, Liow E, Yan F, Yuasa T, Bjarnason GA, Choueiri TK, Heng DYC. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. European Urology 2019, 76: 861-867. PMID: 31445844, PMCID: PMC6858928, DOI: 10.1016/j.eururo.2019.07.048.
• Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell CarcinomaBergerot, Paulo Gustavo et al. ‘Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma’. 1 Jan. 2019 : 63 – 70.
• Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center ExperienceDizman, Nazli et al. ‘Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience’. 1 Jan. 2019 : 171 – 176.
• Biopsychosocial distress and clinical outcome in metastatic renal cell carcinoma.Bergerot CD, Clark KL, Ashing KT, Bergerot PG, Obenchain R, Dizman N, Hsu J, Philip E, Loscalzo M, Pal SK. Biopsychosocial distress and clinical outcome in metastatic renal cell carcinoma. Palliative & Supportive Care 2019, 17: 353-355. PMID: 29911518, DOI: 10.1017/S1478951518000342.
• Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma.Bergerot CD, Battle D, Bergerot PG, Dizman N, Jonasch E, Hammers HJ, George DJ, Bex A, Ljungberg B, Pal SK, Staehler MD. Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. Frontiers In Oncology 2019, 9: 11. PMID: 30723705, PMCID: PMC6349746, DOI: 10.3389/fonc.2019.00011.
• Reliability and validity of the Turkish version of the Diabetes Distress Scale for type 2 diabetes and distress levels of the participantsTelci Çaklili Ö, Feyizoğlu G, Tülü Çolak S, Dizman N, Bozkurt Çakir SI, Oğuz A. Reliability and validity of the Turkish version of the Diabetes Distress Scale for type 2 diabetes and distress levels of the participants Turkish Journal Of Medical Sciences 2020, 50: 464-470. PMID: 31655535, PMCID: PMC7165243, DOI: 10.3906/sag-1903-121.
• Examining Public Communication About Kidney Cancer on Twitter.Sedrak MS, Salgia MM, Decat Bergerot C, Ashing-Giwa K, Cotta BN, Adashek JJ, Dizman N, Wong AR, Pal SK, Bergerot PG. Examining Public Communication About Kidney Cancer on Twitter. JCO Clinical Cancer Informatics 2019, 3: 1-6. PMID: 30860867, PMCID: PMC6874008, DOI: 10.1200/CCI.18.00088.
• Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy.Bergerot CD, Bergerot PG, Philip EJ, Hsu JA, Dizman N, Vaishampayan U, Dorff T, Pal SK. Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy. Journal For Immunotherapy Of Cancer 2019, 7: 71. PMID: 30867071, PMCID: PMC6416952, DOI: 10.1186/s40425-019-0557-5.
• Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.Casadei C, Dizman N, Schepisi G, Cursano MC, Basso U, Santini D, Pal SK, De Giorgi U. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Therapeutic Advances In Medical Oncology 2019, 11: 1758835919890285. PMID: 31803255, PMCID: PMC6878604, DOI: 10.1177/1758835919890285.
• Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil.Bergerot PG, Bergerot CD, Dizman N, Zequi S, Fay A, Dara Y, Maia MC, Cotta BN, Gonçalves EP, Formiga MN, Tariki MS, Clavijo DA, Choueiri TK, Lopes G, Pal SK. Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. Journal Of Global Oncology 2018, 4: 1-8. PMID: 29281478, PMCID: PMC6180782, DOI: 10.1200/JGO.17.00113.
• Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. European Urology 2018, 74: 124-128. PMID: 29685646, DOI: 10.1016/j.eururo.2018.03.032.
• Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma.Adashek JJ, Salgia M, Dizman N, Kessler J, Pal SK. Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma. Case Reports In Oncology 2018, 11: 276-280. PMID: 29867435, PMCID: PMC5981597, DOI: 10.1159/000489995.
• Adjuvant treatment in renal cell carcinoma.Dizman N, Adashek JJ, Hsu J, Bergerot PG, Bergerot CD, Pal SK. Adjuvant treatment in renal cell carcinoma. Clinical Advances In Hematology & Oncology : H&O 2018, 16: 555-563. PMID: 30148828.
• Assessment of distress and quality of life in rare cancers.Bergerot CD, Bergerot PG, Philip EJ, De Domenico EBL, Manhaes MFM, Pedras RN, Salgia MM, Dizman N, Ashing KT, Li M, Dale W, Pal SK. Assessment of distress and quality of life in rare cancers. Psycho-oncology 2018, 27: 2740-2746. PMID: 30171792, DOI: 10.1002/pon.4873.
• Men's CancersCappell, Mitchell S. Principles and practice of hospital medicine. McGraw-Hill Education Medical, 2017.
• Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma?Pal SK, Maia MC, Dizman N, Agarwal N. Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma? European Urology 2017, 72: 972-973. PMID: 28314610, DOI: 10.1016/j.eururo.2017.03.006.
• Cytoreductive nephrectomy: A medical oncologist's perspective.Dizman N, Maia MC, Pal SK. Cytoreductive nephrectomy: A medical oncologist's perspective. Urologic Oncology 2017, 35: 180-182. PMID: 29037531, DOI: 10.1016/j.urolonc.2017.03.018.
• Therapeutic Sequencing in Metastatic Renal Cell Carcinoma.Maia MC, Dizman N, Salgia M, Pal SK. Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. Kidney Cancer 2017, 1: 15-29. PMID: 30334001, PMCID: PMC6179120, DOI: 10.3233/KCA-170006.
• Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden.Maia MC, Bergerot PG, Dizman N, Hsu J, Jones J, Lanman RB, Banks KC, Pal SK. Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. Kidney Cancer 2017, 1: 65-70. PMID: 30334006, PMCID: PMC6179113, DOI: 10.3233/KCA-170007.
• Cholesterol embolization syndrome: A report of two cases.Dizman N, Aydın Bahat K, Özkanlı Ş, Özkök A. Cholesterol embolization syndrome: A report of two cases. Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir 2016, 44: 251-5. PMID: 27138317, DOI: 10.5543/tkda.2015.94587.
• Letter by Dizman et al Regarding Article, "Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study".Dizman N, Cakir IB, Oguz A. Letter by Dizman et al Regarding Article, "Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study". Circulation 2016, 134: e1. PMID: 27358440, DOI: 10.1161/CIRCULATIONAHA.116.022187.
• Advances in treatment of metastatic renal cell carcinoma.Gong J, Gerendash B, Dizman N, Khan A, Pal SK. Advances in treatment of metastatic renal cell carcinoma. Current Opinion In Urology 2016, 26: 439-46. PMID: 27467136, DOI: 10.1097/MOU.0000000000000319.
• Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar.Pal SK, Agarwal N, Dizman N, Sonpavde G. Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. The Lancet. Oncology 2016, 17: 1477-1478. PMID: 27720137, DOI: 10.1016/S1470-2045(16)30493-4.
• Metastasis in renal cell carcinoma: Biology and implications for therapy.Gong J, Maia MC, Dizman N, Govindarajan A, Pal SK. Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian Journal Of Urology 2016, 3: 286-292. PMID: 29264197, PMCID: PMC5730828, DOI: 10.1016/j.ajur.2016.08.006.
• Authors' reply.Dizman N, Aydın Bahat K, Özkanlı Ş, Özkök A. Authors' reply. Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir 2016, 44: 538. PMID: 27665347.
• Biomarker approach harnessed in trials of personalized medicine for bladder cancer.Dizman N, Meza L, Pal SK. Biomarker approach harnessed in trials of personalized medicine for bladder cancer. Nature Medicine 2021, 27: 761-763. PMID: 33941920, DOI: 10.1038/s41591-021-01300-1.
• Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma.Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 4807-4813. PMID: 34130999, DOI: 10.1158/1078-0432.CCR-21-0572.
• Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California.Salgia NJ, Chehrazi-Raffle A, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Medicine 2021, 10: 5671-5680. PMID: 34331372, PMCID: PMC8366095, DOI: 10.1002/cam4.4119.
• Cancer Therapy Targeting CD47/SIRPα.Dizman N, Buchbinder EI. Cancer Therapy Targeting CD47/SIRPα. Cancers 2021, 13 PMID: 34944850, PMCID: PMC8699673, DOI: 10.3390/cancers13246229.